Samet Sahin1, Gul Daglar2, Ebru Menekse2, Busranur Cavdarli3, Tolga Baglan4. 1. Ankara Sereflikochisar State Hospital, General Surgery, Ankara, Turkey. 2. Ankara Numune Training And Research Hospital, General Surgery, Ankara, Turkey. 3. Ankara Numune Training And Research Hospital, Genetics, Ankara, Turkey. 4. Ankara University Faculty Of Medicine, Pathology, Ankara, Turkey.
Abstract
OBJECTIVES: Papillary thyroid cancer (PTC) is the most common well-differentiated thyroid cancer. Lymph node (LN) metastasis is frequently seen in PTC. The effect of BRAFV600E mutation on PTC-associated LN metastasis has not been clearly established. Therefore, we aimed to evaluate the effect of the BRAFV600E mutation in patients with PTC on regional LN metastasis. MATERIAL AND METHODS: Between January 2013 and 2017, sixty-three PTC patients who underwent central lymph node dissection were included into the study. The patients were divided into two groups according to the pathology results of the LN dissection, and these groups were compared for positive BRAFV600E mutations and other clinicopathological findings. RESULTS: BRAFV600E mutation was found to be more significant in the pLN1 group (p= 0.005). Multivariate analysis revealed that nodule size, microcalcifications, and BRAFV600E mutation were associated with lymph node metastasis independent of other parameters. ROC analysis also evaluated the adequacy of the BRAFV600E mutation in predicting the presence of LN involvement. AUC: 0.738 (95%CI:0.6110.866,p: 0.002). CONCLUSION: In our study, independent of other parameters, BRAFV600E gene mutation was found to be effective on lymph node involvement.
OBJECTIVES: Papillary thyroid cancer (PTC) is the most common well-differentiated thyroid cancer. Lymph node (LN) metastasis is frequently seen in PTC. The effect of BRAFV600E mutation on PTC-associated LN metastasis has not been clearly established. Therefore, we aimed to evaluate the effect of the BRAFV600E mutation in patients with PTC on regional LN metastasis. MATERIAL AND METHODS: Between January 2013 and 2017, sixty-three PTC patients who underwent central lymph node dissection were included into the study. The patients were divided into two groups according to the pathology results of the LN dissection, and these groups were compared for positive BRAFV600E mutations and other clinicopathological findings. RESULTS: BRAFV600E mutation was found to be more significant in the pLN1 group (p= 0.005). Multivariate analysis revealed that nodule size, microcalcifications, and BRAFV600E mutation were associated with lymph node metastasis independent of other parameters. ROC analysis also evaluated the adequacy of the BRAFV600E mutation in predicting the presence of LN involvement. AUC: 0.738 (95%CI:0.6110.866,p: 0.002). CONCLUSION: In our study, independent of other parameters, BRAFV600E gene mutation was found to be effective on lymph node involvement.
Authors: José A Pereira; Jaime Jimeno; Joana Miquel; Mar Iglesias; Asumpta Munné; Joan J Sancho; Antonio Sitges-Serra Journal: Surgery Date: 2005-12 Impact factor: 3.982
Authors: Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: Bryan R Haugen; Anna M Sawka; Erik K Alexander; Keith C Bible; Patrizio Caturegli; Gerard M Doherty; Susan J Mandel; John C Morris; Aziza Nassar; Furio Pacini; Martin Schlumberger; Kathryn Schuff; Steven I Sherman; Hilary Somerset; Julie Ann Sosa; David L Steward; Leonard Wartofsky; Michelle D Williams Journal: Thyroid Date: 2017-02-21 Impact factor: 6.568
Authors: Martin Schlumberger; Gertrud Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Furio Pacini; Christoph Reiners; Franco Sánchez Franco; Anthony Toft; Wilmar M Wiersinga Journal: Eur J Endocrinol Date: 2004-02 Impact factor: 6.664